Kenneth Mulvany

Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.